EUVIMEDEUVIMED entdecken
Open Access

Pathological response and tumor regression grading following neoadjuvant chemo‑immunotherapy and chemotherapy in resectable non‑small cell lung cancer

Özge Kaya Korkmaz, Yaren Sari Çataldaş, Nazlican Saltik Barel, Mehmet Büyükevli

Oncology Letters · 22.05.2026 · 32 (1) · 1-12

DOI: 10.3892/ol.2026.15667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 22.05.2026. Verfasst von Özge Kaya Korkmaz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Etlik City Hospital, University of Health Sciences, Ankara, Ankara 06010, Turkey. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent neoadjuvant trials in lung cancer have demonstrated meaningful survival advantages, highlighting the need for standardized assessment of pathologic response in resected specimens. Only two systems are currently recommended for evaluating post-treatment response, namely the International Association for the Study of Lung Cancer (IASLC) tumor regression grading system and the immune-related pathologic response criteria (irPRC). The present study aimed to review and apply histopathologic parameters for assessing tumor regression in non-small cell lung carcinoma (NSCLC) specimens resected after neoadjuvant therapy. A total of 30 NSCLC resections obtained after neoadjuvant therapy between 2022 and 2025 were analyzed. Gross and microscopic evaluations were performed according to IASLC recommendations. Residual viable tumor, fibrosis, inflammation and necrosis were semi-quantitatively assessed according to IASLC and irPRC principles. Major pathologic response (mPR) was defined as ≤10% viable tumor and pathologic complete response (pCR) as 0% viable tumor. Associations with demographic features, treatment modalities and survival outcomes were analyzed. Compared with chemotherapy (CT) alone, chemo-immunotherapy (CIT) exhibited a trend toward a deeper pattern of tumor regression, reflected by lower median viable tumor percentages (7.5 vs. 55.0%) and higher mPR rates (62.5 vs. 22.7%), although these differences did not reach statistical significance. pCR occurred in 37.5% of patients treated with CIT and in 13.6% of patients treated with CT. CIT specimens demonstrated more prominent immune-mediated stromal changes, including greater intratumoral inflammation (32.5 vs. 10.0%) and more frequent lymphocytic patterns. Fibrosis strongly correlated with response (P

Schlagwörter

Stichwörter der Autor:innen

chemo-immunotherapyneoadjuvant therapynon-small cell lung carcinomapathological responsetumor regression grading

Autor:innen und Institutionen

  • Department of Pathology, Etlik City Hospital, University of Health Sciences, Ankara, Ankara 06010, Turkey.
  • Department of Thoracic Surgery, Etlik City Hospital, University of Health Sciences, Ankara, Ankara 06010, Turkey.

Zitieren

APA

Kaya Korkmaz, Ö., Sari Çataldaş, Y., Saltik Barel, N., & Büyükevli, M. (2026). Pathological response and tumor regression grading following neoadjuvant chemo‑immunotherapy and chemotherapy in resectable non‑small cell lung cancer. Oncology Letters, 32(1), 1-12. https://doi.org/10.3892/ol.2026.15667

Vancouver

Kaya Korkmaz Ö, Sari Çataldaş Y, Saltik Barel N, Büyükevli M. Pathological response and tumor regression grading following neoadjuvant chemo‑immunotherapy and chemotherapy in resectable non‑small cell lung cancer. Oncology Letters. 2026;32(1):1-12. doi:10.3892/ol.2026.15667

BibTeX
@article{KayaKorkmaz2026,
  author = {Kaya Korkmaz, Özge and Sari Çataldaş, Yaren and Saltik Barel, Nazlican and Büyükevli, Mehmet},
  title = {Pathological response and tumor regression grading following neoadjuvant chemo‑immunotherapy and chemotherapy in resectable non‑small cell lung cancer},
  journal = {Oncology Letters},
  year = {2026},
  volume = {32},
  number = {1},
  pages = {1--12},
  doi = {10.3892/ol.2026.15667}
}
Kostenlos starten →